Aerie Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.6M
Doctors Paid
13,455
Transactions
57,316
2021 Total
$4.6M
Payment Breakdown by Category
Research$5.3M (36.1%)
Consulting$2.4M (16.6%)
Food & Beverage$1.9M (12.8%)
Travel$658,022 (4.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.3M | 570 | 36.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.3M | 1,590 | 29.3% |
| Consulting Fee | $2.4M | 783 | 16.6% |
| Food and Beverage | $1.9M | 52,187 | 12.8% |
| Travel and Lodging | $658,022 | 2,127 | 4.5% |
| Grant | $47,854 | 18 | 0.3% |
| Education | $28,900 | 29 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $25,200 | 12 | 0.2% |
Payments by Type
General
$9.3M
56,746 transactions
Research
$5.3M
570 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease | $1.9M | 0 | 107 |
| A Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) | $844,942 | 0 | 112 |
| A MULTICENTER, OPEN-LABEL STUDY OF RHOPRESSA (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION IN A REAL-WORLD SETTING | $793,281 | 0 | 98 |
| A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety and Ocular Hypotensive Efficacy and Optimum Concentration to be used Clinically Of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension in the United States | $347,491 | 0 | 65 |
| A Study Assessing AR-13503 Implant Alone and in Combination With Aflibercept in Subjects With nAMD or DME | $317,867 | 0 | 79 |
| A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy (Fuchs) | $295,766 | 0 | 65 |
| A prospective, double-masked, randomized, multicenter, placebo controlled, parallel-group study assessing the safety of two concentrations of netarsudil ophthalmic solution in healthy Japanese/Japanese American volunteers in the United States | $289,851 | 0 | 3 |
| A Randomized, Single Center, Masked, Crossover Study Comparing the Effects of Rhopressa (Netarsudil Ophthalmic Solution) and Timolol on Intraocular Pressure and Retinal Blood Vessel Density in Patients with Ocular Hypertension or Primary Open Angle Glaucoma | $209,227 | 0 | 1 |
| Ophthalmic Assessments of Signs and Symptoms of Dry Eye in Patients Suffering from Self-Reported or Clinician-Diagnosed Dry Eye Disease | $115,375 | 0 | 26 |
| RANDOMIZED, DOUBLE- MASKED, PLACEBO-CONTROLLED EVALUATION OF NETARSUDIL FOR PREVENTION OF CORTICOSTEROID-INDUCED INTRAOCULAR PRESSURE ELEVATION | $43,320 | 0 | 2 |
| Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects using in vivo Erythrocyte Mediated Angiography | $37,188 | 0 | 3 |
| Prospective randomized study to determine whether use of Rhopressa can ammeliorate corneal edema associated with Fuchs dystrophy | $24,890 | 0 | 3 |
| Prospective randomized study to determine whether use of Rhopressa accelerates corneal clearing after removal of Descemet membrane for treatment of Fuchs dystrophy | $20,600 | 0 | 1 |
| A Double-Masked Randomized, Placebo Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated intraocular Pressure | $11,330 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Robert Fechtner, Md, MD | Ophthalmology | Newark, NJ | $276,511 | $0 |
| Dr. Jason Slakter, Md, MD | Specialist | New York, NY | $228,635 | $0 |
| Dr. Amy Miller, Md, MD | Ophthalmology | Dayton, OH | $192,891 | $0 |
| Dr. Jody Piltz-Seymour, M.d, M.D | Glaucoma Specialist | Huntingdon Valley, PA | $192,692 | $0 |
| Shan Lin, Md, MD | Ophthalmology | San Francisco, CA | $170,754 | $0 |
| Jason Bacharach, Md, MD | Ophthalmology | Petaluma, CA | $167,295 | $0 |
| Dr. Quang Nguyen, M.d, M.D | Ophthalmology | La Jolla, CA | $162,572 | $0 |
| Unknown Provider | — | — | $143,956 | $0 |
| Dr. Nathan Radcliffe, M.d, M.D | Ophthalmology | New York, NY | $140,573 | $0 |
| Savak Teymoorian, M.d, M.D | Ophthalmology | Laguna Hills, CA | $125,645 | $0 |
| Dr. Gregory Katz, M.d, M.D | Ophthalmology | Ypsilanti, MI | $123,522 | $0 |
| Dr. Steven Simmons, M.d, M.D | Ophthalmology | Slingerlands, NY | $109,435 | $0 |
| Dr. Thomas Mundorf, Md, MD | Ophthalmology | Charlotte, NC | $101,555 | $0 |
| Dr. Gagan Sawhney, Md, MD | Ophthalmology | Atlanta, GA | $99,662 | $0 |
| Dr. Janet Serle, M.d, M.D | Ophthalmology | New York, NY | $97,566 | $0 |
| Peter Mcdonnell | Ophthalmology | Baltimore, MD | $95,492 | $0 |
| Dr. Robert Weinreb, Md, MD | Ophthalmology | San Diego, CA | $92,843 | $0 |
| Larissa Camejo, Md, MD | Ophthalmology | Palm Beach Gardens, FL | $89,268 | $0 |
| Dr. Marlene Moster, M.d, M.D | Ophthalmology | Sunrise, FL | $86,064 | $0 |
| Sarwat Salim, Md, MD | Glaucoma Specialist | Boston, MA | $85,795 | $0 |
| Constance Okeke, Md, MD | Ophthalmology | Norfolk, VA | $84,494 | $0 |
| Dr. Richard Quinones, Md, MD | Ophthalmology | Homewood, IL | $79,402 | $0 |
| Dr. Oluwatosin Smith, M.d, M.D | Ophthalmology | Dallas, TX | $78,184 | $0 |
| Ahmad Aref, M.d, M.D | Ophthalmology | Chicago, IL | $70,149 | $0 |
| Dr. Anup Khatana, Md, MD | Ophthalmology | Cincinnati, OH | $69,822 | $0 |
About Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc. has made $14.6M in payments to 13,455 healthcare providers, recorded across 57,316 transactions in the CMS Open Payments database. In 2021, the company paid $4.6M. The top product by payment volume is Rhopressa ($5.5M).
Payments were distributed across 62 medical specialties. The top specialty by payment amount is Ophthalmology ($6.4M to 6,498 doctors).
Payment categories include: Food & Beverage ($1.9M), Consulting ($2.4M), Research ($5.3M), Travel & Lodging ($658,022).
Aerie Pharmaceuticals, Inc. is associated with 3 products in the CMS Open Payments database.